25th Jun 2015 08:13
LONDON (Alliance News) - Futura Medical PLC on Thursday said it has now received all necessary regulatory approvals to start its efficacy trial for its MED2002 erectile dysfunction treatment.
Pre-screening of patients has started, and the company said the scope of the trial has been expanded to cover more patients.
"We are delighted that this clinical study of MED2002 has now commenced in the UK. We are using an enhanced trial design which includes an increased number of patients to improve the power of the statistical analysis in this pivotal study," said Chief Executive James Barder.
Shares in Futura were up 2.4% to 37.385 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Futura Medical